Loading
POLD1 (DNA polymerase delta catalytic subunit) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a drug target, a tumour suppressor, a biomarker and a DNA repair gene, and an approved or late-stage drug is recorded against it. Tied to Colorectal cancer, Lung cancer, Breast cancer and 5 more. This dossier gathers the 0 products (0 approved), 0 trials, 0 pathways and 0 resistance routes in the corpus that involve it, with external identifiers so it can be joined to UniProt, ChEMBL, Open Targets and the rest of biology.
As the catalytic component of the trimeric (Pol-delta3 complex) and tetrameric DNA polymerase delta complexes (Pol-delta4 complex), plays a crucial role in high fidelity genome replication, including in lagging strand synthesis, and repair. Exhibits both DNA polymerase and 3'- to 5'-exonuclease activities. Requires the presence of accessory proteins POLD2, POLD3 and POLD4 for full activity. Depending upon the absence (Pol-delta3) or the presence of POLD4 (Pol-delta4), displays differences in catalytic activity. Most notably, expresses higher proofreading activity in the context of Pol-delta3 compared with that of Pol-delta4. Although both Pol-delta3 and Pol-delta4 process Okazaki fragments in vitro, Pol-delta3 may be better suited to fulfill this task, exhibiting near-absence of strand displacement activity compared to Pol-delta4 and stalling on encounter with the 5'-blocking oligonucleotides. Location: Nucleus (UniProt). Locus 19q13.33 (HGNC).
| Cancer | Prevalence | Measure | Note | Source |
|---|---|---|---|---|
| Colorectal cancer | 0.03% | Exonuclease domain hotspot mutation; germline p.Ser478Asn | cBioPortal, exonuclease hotspots: 2 of 7,237 in crc_msk_2026 and 1 of 619 in coadread_dfci_2016; any POLD1 mutation reads 366 of 7,237, 5.1%, in crc_msk_2026, almost all passengers in hypermutated tumours. Germline POLD1 p.Ser478Asn and POLE p.Leu424Val were identified as high-penetrance predisposition variants in families with multiple adenomas and early-onset colorectal cancer, with POLD1 also predisposing to endometrial cancer (Palles 2013). | cBioPortal (TCGA) |
Approximate, population-level figures; the measure column says what was counted. Ranges show the midpoint as a bar.
No product in the corpus is aimed at this target yet.
No trial in the corpus names this target or one of its products.
No recorded escape route names this target.
No pathway diagram carries this target as a node.
No companion diagnostic in the registry measures this target.
No model entry for this target yet; check the cancer entries on the models page.
No open questions recorded for this target yet. Suggest one.
Query for this target: (TITLE:"POLD1" OR ABSTRACT:"POLD1" OR TITLE:"DNA polymerase delta 1, catalytic subunit" OR ABSTRACT:"DNA polymerase delta 1, catalytic subunit" OR TITLE:"DNA polymerase delta catalytic subunit" OR ABSTRACT:"DNA polymerase delta catalytic subunit" OR TITLE:"CDC2" OR ABSTRACT:"CDC2") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about POLD1, not a curated reading list.
The dossier as machine-readable JSON, at /api/v1/dossiers/pold1.json: identifiers from HGNC, Ensembl, UniProt and ChEMBL, products with status, trials, pathways, hotspots, open questions and assays. The full entity record is in the open API at /api/v1/entities/pold1.json. Licence CC BY-NC 4.0.